GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.27. Revenue for the quarter came in at GBP7.64 billion versus the consensus estimate of GBP7.46 billion

·

• 2018 Adjusted EPS Guidance: Growth is subject to uncertainty of timing and impact of possible generic competition to Advair in the US:
• In the event of no substitutable generic competitor to Advair in the US, expect 2018 Adjusted EPS growth to be 4 to 7% CER
• In the event of a mid-year introduction of a substitutable generic competitor to Advair in the US, expect full year 2018 US Advair sales of around £750 million at CER (US$1.30/£1) with Adjusted EPS flat to down 3% CER
• Both scenarios reflect the benefit of US tax reform with expected 2018 effective tax rate on Adjusted profits of 19-20%
• Continue to expect 80p dividend for 2018

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.